Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with ...
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74.
US private biotech Cancer Prevention Pharmaceuticals has filed a marketing application in Europe for CPP-1X/sul, a preventative treatment for patients with familial adenomatous polyposis (FAP).